Malte Peters - 19 Aug 2025 Form 4 Insider Report for HOOKIPA Pharma Inc. (HOOK)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: HOOK
Reported as of: 19 Aug 2025
Net transaction value: -$20,684
SEC form: 4
Accepted by SEC: 09 Oct 2025, 16:22:11 UTC
Prior SEC filing: 23 Jul 2025
Next SEC filing: 04 Nov 2025
Source filing: View source filing
Reporting owner signature: Malte Peters

Key filing fact

Malte Peters filed Form 4 for HOOKIPA Pharma Inc. (HOOK) on 09 Oct 2025.

Key facts

This page summarizes Malte Peters's Form 4 filing for HOOKIPA Pharma Inc. (HOOK).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 Oct 2025, 16:22.

Change

Previous filing in this sequence was filed on 23 Jul 2025.
Current net transaction value: -$20,684.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001876563 Primary reporting owner

Peters Malte

Relationship: Chief Executive Officer, Director
Address: C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK
Signature: Malte Peters
Signature date: 09 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HOOK transaction

Common Stock

Sale

Transaction value: $20,684
Shares: -25,172
Change %: -32%
Price: $0.8217
Shares after: 54,347
Date: 19 Aug 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8205 to $0.8225 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.